We are a venture capital firm investing in life science companies covering start-ups to later stage companies. Based in Heidelberg, we invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment modalities and pharmaceuticals, next generation enabling technology platforms or innovations in the diagnostics and medical device area. As an independent and focused team we move quickly with short decision timelines. However, once engaged, we offer our portfolio companies the time and the attention they deserve to make them successful.

EMBL Ventures manages two Funds with a total of

Immatics appoints Katina Dorton as
Chief Financial Officer

Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy announces the appointment of Katina Dorton as Chief Financial Officer (CFO), effective immediately.

Continue Reading

Crescendo Biologics Appoints Dr Kevin Johnson as Chairman

Antibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus

Continue Reading

EMBL Ventures co-leads Luxendo Series A financing round

Luxendo, a start-up company launched by the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBLEM Technology Transfer (EMBLEM) in Heidelberg announced the closing of a EUR 6 Million Series A financing co-led by EMBL Ventures, Heidelberg and Life Science Partners (LSP), Amsterdam.

Continue Reading